PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer

Prostate cancer (PCa) is the second leading cause of cancer death for men in the United States. While organ-confined disease has reasonable expectation of cure, metastatic PCa is universally fatal upon recurrence during hormone therapy, a stage termed castration-resistant prostate cancer (CRPC). Unt...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Nicolas, Gallagher, Peter T., Neupane, Neermala Poudel, Mandigo, Amy C., McCann, Jennifer K., Dylgjeri, Emanuela, Vasilevskaya, Irina, McNair, Christopher, Paller, Channing J., Kelly, Wm. Kevin, Knudsen, Karen E., Shafi, Ayesha A., Schiewer, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055378/
https://www.ncbi.nlm.nih.gov/pubmed/36993449
http://dx.doi.org/10.1101/2023.03.23.533944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055378/
https://www.ncbi.nlm.nih.gov/pubmed/36993449
http://dx.doi.org/10.1101/2023.03.23.533944

Ejemplares similares